Authors
Latest:
Dr Patel on the FDA Approval of Ide-Cel for Triple Class–Exposed R/R Multiple MyelomaKrina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.
Latest:
Dr Zarrabi on Questions Regarding the Use of Triplet Therapy in Prostate CancerKevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.
Latest:
Dr. Dent on the Clinical Implications of the MONALEESA-2 Trial in HR+/HER2- Breast CancerSusan Faye Dent, MD, discusses the clinical implications of the phase 3 MONALEESA-2 trial in hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Extermann on the Significance of Novel Treatment Options in HER2+ Breast CancerMartine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.
Latest:
The Evolving Treatment Landscape of Biliary Tract CancersClosing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.
Latest:
Dr Hays on Unmet Needs in CRCJohn L. Hays, MD, PhD, discusses unmet needs for patients with colorectal cancer and future directions for research in this disease.
Latest:
Dr Talcott on Treatment De-Escalation in Elderly Patients With Breast CancerWesley J. Talcott, MD, MBA, discusses the importance of de-escalating therapy in patients with breast cancer, highlighting use of personalized treatment approaches.
Latest:
Dr. Rajdev on Detecting HER2 Positivity in GI CancerLakshmi Rajdev, MD, MS, discusses detecting HER2 positivity in patients with gastrointestinal cancers.
Latest:
Closing Thoughts on Evolving Antibody-Drug Conjugate LandscapeThe expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
Latest:
Reviewing Best Practices in the Surgical Management of Breast Cancer: Post-Surgery Outcomes in Stage IV DiseaseIn this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.
Latest:
Direct Partnership With Patients May Accelerate Cancer Research and Precision OncologyDuring the past several decades, cancer research has produced revolutionary discoveries leading to dramatic results for many patients.
Latest:
Clinical Updates for the Management of Lung Cancer Brain MetastasesAs improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.
Latest:
Zhao on Existing Medical Conditions and Cancer Clinical Trial EnrollmentYayi Zhao, discusses how the prevalence of existing medical conditions and clinical factors may vary by race and effect eligibility for enrollment in clinical trials in patients with cancer.
Latest:
Physicians Must Become Advocates to Play a Role in Community Oncology’s FutureAlthough some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.
Latest:
Dr Ramnaraign on Retrospective Data For irAEs in Older Patients With Kidney CancerBrian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.
Latest:
Dr. Nichols on the Prognosis of Patients With VHL DiseaseKim E. Nichols, MD, discusses the prognosis of patients with von Hippel-Lindau disease.
Latest:
Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal CancerThe panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.
Latest:
Dr. Sklavenitis-Pistofidis on Single-Cell Dissection of Immune Cells in Smoldering MyelomaRomanos Sklavenitis-Pistofidis, MD, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.
Latest:
More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New StudyA survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.
Latest:
Niraparib Plus Abiraterone and Prednisone Elicits OS Benefit in BRCA1/2+ mCRPCThe addition of niraparib to abiraterone acetate and prednisone led to a benefit in overall survival vs treatment with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.
Latest:
Dr. Wei on the Potential Implications of the CompassHER2 RD Trial in HER2+ Breast CancerMei Wei, MD, discusses the potential clinical implications of the ongoing, phase 3 CompassHER2 RD trial in HER2-positive breast cancer.
Latest:
Why Oncologists Should Know More About Medical MarijuanaIncreasingly, patients are asking oncologists for guidance and recommendations for the use of medical marijuana. However, finding those answers is challenging because of the federal government.
Latest:
Now is the Time to Improve Diversity in Cancer Clinical TrialFewer African American and Hispanic patients participated in oncology trials from 2003 to 2016 than from 1996 to 2002.
Latest:
Dr. Evens on the Design of a Retrospective Analysis Evaluating Salvage Regimens in R/R Hodgkin LymphomaAndrew M. Evens, DO, MSc, discusses the design of a retrospective analysis evaluating in relapsed/refractory classic Hodgkin lymphoma.
Latest:
Dr Srour on the Ongoing Investigation of CAR T-Cell Therapy in Advanced RCCSamer A. Srour, MB ChB, MS, discusses the investigation of the allogeneic CAR T-cell therapy CTX131 in advanced clear cell renal cell carcinoma.
Latest:
Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL AmyloidosisMorie A. Gertz, MD, discusses the rationale for the phase 3 AFFIRM-AL trial in patients with amyloid light chain amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.
Latest:
Reviewing Best Practices in the Surgical Management of Breast Cancer: Post-Surgery Outcomes in Stage IV DiseaseIn this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.
